Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118456 · ClinicalTrials.gov registry record · Phase 1
Study of Oral AEE788 in Adults With Advanced Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 189
- Enrollment target
NCT00118456 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 189 participants.
The verdict
NCT00118456, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 189 participants
- Enrollment target
Study Summary
AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will assess the safety, pharmacokinetic (PK)/pharmacodynamic (PD) profiles and clinical activity of AEE788 in advanced cancers.
Interventions
- DRUG AEE788
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2003-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118456
The ClinicalTrials.gov registry entry for NCT00118456 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AEE788 is the first listed.
NCT00118456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118456 about?
NCT00118456 is a clinical study titled "Study of Oral AEE788 in Adults With Advanced Cancer". AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will assess the safety, pharma...
What is the current status of trial NCT00118456?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 189 participants. The study started on 2003-07.
What interventions are being tested in trial NCT00118456?
The interventions under investigation include: AEE788 (DRUG).
Who is sponsoring clinical trial NCT00118456?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.